ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -34 مورد

Fesoterodine: Pediatric drug information

Fesoterodine: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Fesoterodine: Drug information" and "Fesoterodine: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Toviaz
Brand Names: Canada
  • SANDOZ Fesoterodine Fumarate;
  • Toviaz
Therapeutic Category
  • Anticholinergic Agent
Dosing: Pediatric

Note: Toviaz is an extended-release dosage form; patients must be able to swallow tablets whole.

Neurogenic detrusor overactivity

Neurogenic detrusor overactivity (NDO):

Children ≥6 years and Adolescents:

>25 kg to ≤35 kg: Oral: 4 mg once daily; may be increased to 8 mg once daily based on individual response and tolerability; in patients >35 kg, doses were titrated after ≥1 week of therapy; maximum daily dose: 8 mg/day.

>35 kg: Oral: Initial: 4 mg once daily; after 1 week of therapy, increase dose to 8 mg once daily; maximum daily dose: 8 mg/day.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Note: Pediatric dosing recommendations are based on extrapolation of adult data and assumption of similar proportional renal elimination.

Children ≥6 years and Adolescents: Oral:

eGFR 30 to 89 mL/minute/1.73 m2:

>25 kg to ≤35 kg: Maximum daily dose: 4 mg/day.

>35 kg: Initial dose: No dosage adjustment needed; maximum daily dose: 8 mg/day.

eGFR 15 to 29 mL/minute/1.73 m2:

>25 kg to ≤35 kg: Use is not recommended.

>35 kg: Maximum daily dose: 4 mg/day.

eGFR <15 mL/minute/1.73 m2: All pediatric patients: Use is not recommended.

Hemodialysis: All pediatric patients: Use is not recommended.

Dosing: Liver Impairment: Pediatric

Children ≥6 years and Adolescents:

Mild to moderate impairment: No dosage adjustment necessary.

Severe impairment: Use is not recommended; has not been studied.

Dosing: Adult

(For additional information see "Fesoterodine: Drug information")

Overactive bladder

Overactive bladder: Oral: 4 mg once daily; may be increased to a maximum dose of 8 mg once daily based on individual response and tolerability

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute: Maximum dose: 4 mg once daily

Dosing: Liver Impairment: Adult

Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.

Severe impairment (Child-Pugh class C): Use is not recommended; has not been studied.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are reported for overactive bladder (OAB) in adults unless otherwise noted as neurogenic detrusor overactivity (NDO) in children and adolescents.

>10%: Gastrointestinal: Diarrhea (NDO: 7% to 12%), xerostomia (NDO: 7% to 10%; OAB: 19% to 35%)

1% to 10%:

Cardiovascular: Peripheral edema (1%)

Dermatologic: Skin rash (1%)

Endocrine & metabolic: Weight gain (NDO: 5%)

Gastrointestinal: Abdominal pain (NDO: 5% to 7%; OAB: 1%), constipation (NDO: 7%; OAB: 4% to 6%), dyspepsia (2%), nausea (NDO: 2% to 5%; OAB: 2%)

Genitourinary: Dysuria (1% to 2%), urinary retention (1%), urinary tract infection (NDO: 2% to 10%; OAB: 4%)

Hepatic: Increased gamma-glutamyl transferase (1%), increased serum alanine aminotransferase (1%)

Nervous system: Headache (NDO: 5% to 7%), insomnia (1%)

Neuromuscular & skeletal: Back pain (2%)

Ophthalmic: Accommodation disturbance (NDO: ≤6%), blurred vision (NDO: ≤6%), dry eye syndrome (1% to 4%), myopia (NDO: ≤6%)

Respiratory: Cough (2%), dry throat (2%), upper respiratory tract infection (3%)

<1%:

Cardiovascular: Angina pectoris, chest pain, prolonged QT interval on ECG

Gastrointestinal: Decreased gastrointestinal motility, diverticulitis of the gastrointestinal tract, gastroenteritis, irritable bowel syndrome

Frequency not defined (any indication): Cardiovascular: Increased heart rate

Postmarketing (any indication):

Cardiovascular: Palpitations

Dermatologic: Pruritus, urticaria

Gastrointestinal: Oral hypoesthesia

Hypersensitivity: Angioedema, facial edema, hypersensitivity reaction

Nervous system: Confusion, dizziness, drowsiness

Contraindications

Hypersensitivity (eg, angioedema) to fesoterodine, tolterodine, or any component of the formulation; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma.

Warnings/Precautions

Concerns related to adverse effects:

• Angioedema: Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported; may be life-threatening. Cases may occur after the initial dose or after multiple doses. Discontinue immediately if tongue, hypopharynx, or larynx are involved.

• CNS effects: Anticholinergics may cause drowsiness, dizziness, headache, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.

• Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.

Disease-related concerns:

• Bladder flow obstruction: Use is not recommended in patients with significant bladder outlet obstruction; may increase the risk of urinary retention.

• GI obstructive disorders: Use is not recommended in patients with decreased GI motility (eg, severe constipation).

• Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.

• Hepatic impairment: Use is not recommended in patients with severe hepatic impairment; has not been studied.

• Myasthenia gravis: Use with caution in patients with myasthenia gravis.

• Renal impairment: Use with caution in patients with renal impairment. Dose adjustment recommended in patients with severe renal impairment (CrCl <30 mL/minute).

Special populations:

• Older adult: Risk of adverse effects may be increased in older adult patients.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet Extended Release 24 Hour, Oral, as fumarate:

Toviaz: 4 mg, 8 mg [contains fd&c blue #2 (indigo carm) aluminum lake, soybean lecithin]

Generic: 4 mg, 8 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablet, 24-hour (Fesoterodine Fumarate ER Oral)

4 mg (per each): $13.41 - $13.55

8 mg (per each): $13.41 - $13.55

Tablet, 24-hour (Toviaz Oral)

4 mg (per each): $11.60

8 mg (per each): $11.60

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet Extended Release 24 Hour, Oral, as fumarate:

Toviaz: 4 mg, 8 mg [contains fd&c blue #2 (indigo carm) aluminum lake, soybean lecithin]

Generic: 4 mg, 8 mg

Administration: Pediatric

Oral: May be administered with or without food. Swallow whole; do not chew, crush, or divide.

Administration: Adult

Oral: May be administered with or without food. Swallow whole; do not chew, crush, or divide.

Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation is available. Consider switching to tolterodine immediate release, since both fesoterodine and tolterodine are metabolized to the same active drug.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from moisture.

Use

Treatment of neurogenic detrusor overactivity (NDO) (FDA approved in pediatric patients ≥6 years of age weighing >25 kg); treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence (FDA approved in adults).

Medication Safety Issues
Sound-alike/look-alike issues:

Fesoterodine may be confused with fexofenadine, tolterodine

Adult Older: High-Risk Medication:

Beers Criteria: Fesoterodine is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of CYP2D6 (Minor), CYP3A4 (Major with inhibitors), CYP3A4 (Minor with inducers); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Acetylcholinesterase Inhibitors: May decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Acetylcholinesterase Inhibitors. Risk C: Monitor

Aclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Acrivastine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Agents with Clinically Relevant Anticholinergic Effects: May increase anticholinergic effects of Fesoterodine. Risk C: Monitor

Alcohol (Ethyl): May increase CNS depressant effects of Fesoterodine. Risk C: Monitor

Amantadine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Benperidol: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Benperidol. Risk C: Monitor

Benztropine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Benztropine. Risk C: Monitor

Biperiden: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Biperiden. Risk C: Monitor

Bornaprine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Botulinum Toxin-Containing Products: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Bromperidol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bromperidol. Risk C: Monitor

Buclizine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Buclizine. Risk C: Monitor

Cannabinoid-Containing Products: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of Cannabinoid-Containing Products. Risk C: Monitor

Chlorprothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Chlorprothixene. Risk C: Monitor

Cimetropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Cimetropium. Risk X: Avoid

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

CloZAPine: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider Therapy Modification

Cyclizine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

CYP2D6 Inhibitors (Strong): May increase active metabolite exposure of Fesoterodine. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease active metabolite exposure of Fesoterodine. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase active metabolite exposure of Fesoterodine. Management: Limit fesoterodine doses to 4 mg daily in patients who are also receiving strong CYP3A4 inhibitors. This combination is not recommended in pediatric patients weighing 25 kg up to 35 kg. Risk D: Consider Therapy Modification

Darifenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Darifenacin. Risk C: Monitor

Dicyclomine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dicyclomine. Risk C: Monitor

Dimethindene (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dimethindene (Systemic). Risk C: Monitor

DroNABinol: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of DroNABinol. Risk X: Avoid

Eluxadoline: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Eluxadoline. Risk X: Avoid

FluPHENAZine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Gastrointestinal Agents (Prokinetic): Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Gastrointestinal Agents (Prokinetic). Risk C: Monitor

Gepotidacin: May decrease anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Glucagon: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor

Glycopyrrolate (Oral Inhalation): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Oral Inhalation). Risk X: Avoid

Glycopyrrolate (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Systemic). Risk C: Monitor

Glycopyrronium (Topical): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Ipratropium (Nasal): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ipratropium (Oral Inhalation): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Itopride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Itopride. Risk C: Monitor

Itraconazole: May increase active metabolite exposure of Fesoterodine. Management: Limit fesoterodine doses to 4 mg daily when combined with itraconazole. Use of fesoterodine with itraconazole, or for 2 weeks after itraconazole discontinuation, in patients with moderate to severe hepatic or renal impairment is contraindicated. Risk D: Consider Therapy Modification

Levosulpiride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Levosulpiride. Risk X: Avoid

Maprotiline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Maprotiline. Risk C: Monitor

Melperone: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Methotrimeprazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methotrimeprazine. Risk C: Monitor

Methscopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methscopolamine. Risk C: Monitor

Mirabegron: May increase adverse/toxic effects of Fesoterodine. Mirabegron may increase active metabolite exposure of Fesoterodine. Risk C: Monitor

Nitroglycerin: Agents with Clinically Relevant Anticholinergic Effects may decrease absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor

OLANZapine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OLANZapine. Risk C: Monitor

Opioid Agonists: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor

Opipramol: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Oxatomide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

OxyBUTYnin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OxyBUTYnin. Risk C: Monitor

Perazine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Perphenazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Perphenazine. Risk C: Monitor

Potassium Chloride: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid

Potassium Citrate: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid

Pramlintide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. These effects are specific to the GI tract. Risk X: Avoid

Promethazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Promethazine. Risk C: Monitor

Propantheline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Propantheline. Risk C: Monitor

Propiverine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

QuiNIDine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ramosetron: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Ramosetron. Risk C: Monitor

Revefenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Revefenacin. Risk X: Avoid

Rivastigmine: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Rivastigmine. Rivastigmine may decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider Therapy Modification

Scopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Scopolamine. Risk C: Monitor

Secretin: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider Therapy Modification

Sofpironium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Sofpironium. Risk X: Avoid

Thiazide and Thiazide-Like Diuretics: Agents with Clinically Relevant Anticholinergic Effects may increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Thiothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Thiothixene. Risk C: Monitor

Tiapride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Tiapride. Risk C: Monitor

Tiotropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tiotropium. Risk X: Avoid

Tolterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tolterodine. Risk C: Monitor

Topiramate: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Topiramate. Risk C: Monitor

Trimethobenzamide: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trimethobenzamide. Risk C: Monitor

Trospium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trospium. Risk C: Monitor

Umeclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Zuclopenthixol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Zuclopenthixol. Risk C: Monitor

Pregnancy Considerations

Adverse effects have been observed in some animal reproduction studies.

Monitoring Parameters

Anticholinergic effects (ie, dry mouth, constipation, dizziness, blurred vision, urinary retention); renal function; hepatic function; signs/symptoms angioedema or heat intolerance.

Mechanism of Action

Fesoterodine acts as a prodrug and is converted to an active metabolite, 5-hydroxymethyl tolterodine (5-HMT); 5-HMT is responsible for fesoterodine’s antimuscarinic activity and acts as a competitive antagonist of muscarinic receptors.

Urinary bladder contractions are mediated by muscarinic receptors; fesoterodine inhibits the receptors in the bladder preventing symptoms of urgency and frequency.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Well absorbed.

Distribution: 5-HMT:

Children ≥6 years and Adolescents ≤17 years (weighing ≥35 kg): Oral: 68 L.

Adults: IV: Vd: 169 L.

Protein binding: 5-HMT: ~50% (primarily to albumin and alpha1-acid glycoprotein).

Metabolism: Fesoterodine is rapidly and extensively metabolized to its active metabolite (5-hydroxymethyl tolterodine; 5-HMT) by nonspecific esterases; 5-HMT is further metabolized via CYP2D6 and CYP3A4 to inactive metabolites.

Bioavailability: 5-HMT: 52%.

Half-life elimination:

Children ≥6 years and Adolescents ≤17 years (weighing ≥35 kg): 7.73 hours.

Adults: ~7 hours.

Time to peak, plasma: 5-HMT: Cmax ~2-fold higher in poor CYP2D6 metabolizers.

Children ≥6 years and Adolescents ≤17 years (weighing ≥35 kg): 2.55 hours.

Adults: Median: ~5 hours.

Excretion: Urine (~70%; 16% as 5-HMT, ~53% as inactive metabolites); feces (7%).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Plasma concentrations of the active metabolite are increased in patients with renal impairment.

Hepatic function impairment: Plasma concentrations of the active metabolite are increased in patients with hepatic impairment.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (BD) Bangladesh: Fesotrex;
  • (BE) Belgium: Fesoterodine ab | Toviaz;
  • (CH) Switzerland: Fesoterodine zentiva | Toviaz;
  • (CZ) Czech Republic: Fesoterodine aristo | Sokar | Toviaz;
  • (DE) Germany: Toviaz;
  • (ES) Spain: Fesoterodina alter | Fesoterodina aristo | Fesoterodina aurovitas | Fesoterodina cinfa | Fesoterodina normon | Fesoterodina stada | Toviaz;
  • (FR) France: Fesoterodine arrow | Fesoterodine biogaran | Fesoterodine cristers lp | Fesoterodine teva | Fesoterodine zentiva | Toviaz;
  • (GB) United Kingdom: Fesoterodine | Fesoterodine fumarate aristo | Fesoterodine fumarate zentiva | Fesoterodine xiromed | Teraleve;
  • (GR) Greece: Toviaz;
  • (HK) Hong Kong: Toviaz;
  • (ID) Indonesia: Toviaz;
  • (IE) Ireland: Fesoterodine clonmel | Fesoterodine pinewood | Toviaz;
  • (IN) India: Fesobig;
  • (IT) Italy: Toviaz;
  • (JP) Japan: Toviaz;
  • (LT) Lithuania: Toviaz;
  • (LU) Luxembourg: Toviaz;
  • (MY) Malaysia: Toviaz;
  • (NL) Netherlands: Fesoterodine accord | Fesoterodine aristo | Fesoterodine CF | Fesoterodine teva | Fesoterodine xiromed | Toviaz;
  • (NO) Norway: Fesoterodine aristo | Fesoterodine eg | Fesoterodine zentiva | Toviaz;
  • (PH) Philippines: Toviaz;
  • (PL) Poland: Toviaz;
  • (PR) Puerto Rico: Toviaz;
  • (PT) Portugal: Tosef;
  • (RO) Romania: Toviaz;
  • (RU) Russian Federation: Toviaz;
  • (SE) Sweden: Fesoterodin Accord | Fesoterodin medical valley | Fesoterodine 2care4 | Fesoterodine zentiva | Toviaz;
  • (SK) Slovakia: Sokar | Toviaz;
  • (TR) Turkey: Fosetaz | Toviaz
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. Obstet Gynecol. 2015;126(5):e66-e81. [PubMed 26488524]
  3. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [published correction appears in: Eur Urol. 2008;53(6):1319]. Eur Urol. 2007;52(4):1204-1212. doi: 10.1016/j.eururo.2007.07.009. [PubMed 17651893]
  4. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome [published correction appears in: Urology. 2009;74(3):716]. Urology. 2008;71(5):839-843. doi: 10.1016/j.urology.2007.12.017 [PubMed 18342923]
  5. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. J Urol. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183 [PubMed 34384237]
  6. Michel M. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9(10):1787-1796. [PubMed 18570610]
  7. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178(5):2488-2494. [PubMed 17937959]
  8. Toviaz (fesoterodine) [prescribing information]. New York, NY: Pfizer Inc; November 2021.
  9. Toviaz (fesoterodine) [prescribing information]. New York, NY: Pfizer Inc; February 2024.
Topic 132467 Version 131.0